What is CJC-1295 DAC? n

CJC-1295 DAC Research: Overview, Mechanism & Data

CJC-1295 DAC is a novel growth hormone-releasing hormone (GHRH) analog distinguished by its conjugation with a Drug Affinity Complex (DAC), which facilitates extended binding to circulating albumin. This unique modification is designed to significantly prolong its half-life and duration of action, offering a distinct profile for investigative studies compared to unmodified GHRH analogs.

Currently, research interest in CJC-1295 DAC is nascent but growing, as reflected by one indexed publication in PubMed exploring its characteristics, and zero registered studies on ClinicalTrials.gov, indicating that its primary current focus remains within early-stage research.

Introduction to CJC-1295 DAC: A Research Perspective

CJC-1295 DAC represents a specialized synthetic peptide engineered for research applications, primarily within the scope of growth hormone secretagogue investigations. Classified as a Growth Hormone-Releasing Hormone (GHRH) analog, its primary distinguishing feature is the incorporation of a Drug Affinity Complex (DAC). This modification is a key design element intended to significantly extend the peptide’s pharmacokinetic profile through reversible, yet strong, binding to endogenous serum albumin. In preclinical research models, GHRH analogs like CJC-1295 DAC are utilized to explore the regulation of the somatotropic axis, specifically focusing on the pulsatile release and synthesis of growth hormone (GH) from the anterior pituitary gland.

The strategic design of CJC-1295 DAC aims to provide a more stable and prolonged stimulus to GHRH receptors compared to unmodified GHRH, thereby facilitating sustained GH secretion. This sustained stimulation is of particular interest in research concerning metabolic regulation, body composition, and endocrine physiology where an extended duration of action is advantageous for studying chronic effects. Researchers employing CJC-1295 DAC investigate its potential to modulate various physiological processes influenced by the growth hormone pathway, always within controlled laboratory environments and in accordance with strict research-use-only guidelines.

It is important for researchers to note that while the GHRH class of peptides has been extensively studied, CJC-1295 DAC itself has a limited publication footprint. Current scientific literature indicates only one PubMed-indexed publication directly addressing CJC-1295 DAC, and no registered studies on ClinicalTrials.gov. This highlights the early stage of research for this specific compound and underscores the necessity for rigorous, well-controlled research peptide investigations to further characterize its properties and effects.

Chemical Structure and Rational Design of CJC-1295 DAC

CJC-1295 DAC is a synthetically derived peptide that builds upon the fundamental structure of naturally occurring Growth Hormone-Releasing Hormone (GHRH). Native human GHRH is a 44-amino acid peptide, but CJC-1295 DAC is typically based on a shorter, N-terminal fragment of GHRH, often a 29- or 30-amino acid sequence, which retains full biological activity and receptor affinity. The rational design of CJC-1295 DAC involves specific amino acid substitutions within this core peptide sequence to enhance its stability against enzymatic degradation, thereby improving its proteolytic resistance in vitro and in vivo.

The most critical feature distinguishing CJC-1295 DAC from earlier GHRH analogs and the unmodified GHRH peptide is the covalent conjugation of a Drug Affinity Complex (DAC) moiety. This complex is typically an inert, non-immunogenic derivative, such as maleimidopropionic acid (MPA), which is chemically linked to a specific amino acid residue within the peptide sequence, often a lysine residue at the C-terminus. The maleimide group of the DAC forms a stable, reversible covalent bond with the free thiol group of cysteine-34, an abundant residue on circulating human serum albumin. This interaction is central to the extended pharmacokinetic profile of CJC-1295 DAC.

Comparative Structural Features

The design modifications in CJC-1295 DAC compared to native GHRH are strategic, aiming to optimize both potency and duration of action. The following table highlights key differences:

Feature	Native Human GHRH (1-44)	CJC-1295 DAC
Peptide Length	44 amino acids	Typically 29 or 30 amino acids (e.g., GHRH (1-29) analog)
Proteolytic Stability	Relatively low; rapid degradation by serum proteases	Enhanced due to amino acid substitutions (e.g., D-Ala at position 2, Lys substitutions)
Albumin Binding	Minimal to none	High affinity, covalent binding via Drug Affinity Complex (DAC)
Mechanism of Half-life Extension	N/A	Reduced renal clearance, protection from enzymatic degradation via albumin binding

This rational design ensures that CJC-1295 DAC, once administered in a research setting, binds to endogenous albumin, essentially creating a circulating reservoir of the active peptide. This complex is significantly larger than the free peptide, reducing its renal clearance and providing protection from proteolytic enzymes, thereby drastically extending its half-life and duration of action within experimental models. The precision in its chemical synthesis is paramount, requiring rigorous quality testing to ensure purity, sequence integrity, and accurate DAC conjugation.

Mechanism of Action: GHRH Receptor Activation and Signal Transduction

The primary mechanism of action for CJC-1295 DAC, as with other GHRH analogs, revolves around its specific interaction with the Growth Hormone-Releasing Hormone Receptor (GHRH-R). These receptors are predominantly expressed on the somatotroph cells located in the anterior pituitary gland, which are responsible for the synthesis and secretion of growth hormone (GH). CJC-1295 DAC acts as an agonist at these receptors, mimicking the physiological effects of endogenous GHRH.

Upon binding of CJC-1295 DAC to the GHRH-R, a conformational change occurs in the receptor protein. The GHRH-R belongs to the Class B family of G-protein coupled receptors (GPCRs). Activation of the GHRH-R leads to the dissociation of its associated heterotrimeric G-protein, specifically the Gs subunit. The activated Gs subunit then stimulates adenylyl cyclase, an enzyme embedded in the cell membrane. Adenylyl cyclase catalyzes the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), a crucial intracellular second messenger.

Intracellular Signaling Cascade

cAMP Elevation: The increased intracellular concentration of cAMP is a pivotal step.
Protein Kinase A (PKA) Activation: cAMP binds to the regulatory subunits of Protein Kinase A (PKA), causing their dissociation from the catalytic subunits. The now free and active catalytic subunits of PKA can phosphorylate various intracellular proteins.
Gene Transcription and GH Synthesis: PKA-mediated phosphorylation events activate transcription factors, such as cAMP response element-binding protein (CREB). Activated CREB binds to specific DNA sequences (cAMP response elements, CREs) in the promoter regions of genes involved in GH synthesis and secretion. This leads to an upregulation of GH mRNA transcription and subsequent translation into mature GH protein.
GH Secretion: PKA activation also influences the intracellular calcium levels and enhances the exocytosis of pre-synthesized GH from secretory granules within somatotrophs. This results in the pulsatile release of GH into the systemic circulation.

While the Drug Affinity Complex (DAC) component of CJC-1295 DAC does not directly participate in the receptor binding or subsequent signal transduction cascade, it plays an indirect yet critical role. By binding to albumin, the DAC moiety extends the systemic exposure of the GHRH analog, ensuring a more prolonged and sustained activation of GHRH receptors. This extended pharmacokinetic profile allows for a more consistent stimulation of the GHRH-R, potentially leading to a more stable and extended pattern of GH release in preclinical models, which is valuable for studying chronic effects on the somatotropic axis. For a more detailed breakdown of the GHRH-R mechanism, please refer to our dedicated page on CJC-1295 DAC’s mechanism of action.

The Drug Affinity Complex (DAC) Technology: Principles and Application in CJC-1295

The Drug Affinity Complex (DAC) technology represents a sophisticated strategy in peptide engineering aimed at prolonging the in vivo half-life of research peptides, thereby enhancing their pharmacokinetic profile and potentially reducing dosing frequency in experimental protocols. At its core, DAC involves the covalent conjugation of a peptide of interest with a small, proprietary albumin-binding moiety. Human serum albumin (HSA) is the most abundant protein in plasma, boasting a half-life of approximately 19 days in humans, making it an ideal carrier for extending the systemic circulation of conjugated molecules. The DAC moiety is specifically designed to bind reversibly but with high affinity to endogenous albumin, essentially transforming the peptide into an albumin-peptide complex. This complex significantly increases the peptide’s molecular size and reduces its renal clearance, which is a primary elimination pathway for smaller peptides. Furthermore, albumin binding protects the conjugated peptide from enzymatic degradation, contributing to its enhanced stability in circulation, a critical factor for consistent research outcomes.

For CJC-1295, a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), the integration of DAC technology was a strategic design choice to overcome the inherent short half-life of native GHRH and earlier GHRH analogs. Unmodified GHRH is rapidly metabolized by dipeptidyl peptidase-IV (DPP-IV) and cleared renally, limiting its biological utility without frequent administration in research settings. By conjugating CJC-1295 with the DAC moiety, researchers engineered CJC-1295 DAC to form a stable complex with circulating albumin in preclinical models. This conjugation is precisely designed to maintain the biological activity of CJC-1295, ensuring that the GHRH analog retains its ability to interact with the GHRH receptor while benefiting from extended systemic exposure. The DAC modification positions CJC-1295 DAC as a valuable tool for investigations requiring sustained GHRH receptor agonism, facilitating studies into long-term effects on the somatotropic axis in animal models.

The application of DAC technology to CJC-1295 offers several distinct advantages for research studies, primarily by optimizing its pharmacokinetic properties. These benefits are particularly relevant for designing robust and interpretable preclinical experiments:

Extended Half-Life: Significantly prolongs the duration of action compared to unmodified GHRH or short-acting analogs, allowing for sustained receptor engagement.
Reduced Dosing Frequency: Enables less frequent administration in chronic preclinical studies, simplifying experimental design, minimizing handling stress on animal models, and reducing variability.
Consistent Exposure: Provides a more stable and sustained concentration of the active peptide in circulation, leading to more consistent and predictable pharmacodynamic effects over time.
Improved Bioavailability: Protection from enzymatic degradation and reduced renal clearance contribute to more reliable and extended systemic exposure, crucial for dose-response characterization.

These attributes make CJC-1295 DAC particularly useful for chronic models investigating conditions related to growth hormone deficiency or for detailed pharmacokinetic/pharmacodynamic profiling experiments where sustained agonism is desired.

Pharmacokinetic Profile: Albumin Binding, Half-Life Extension, and Bioavailability

The distinctive pharmacokinetic profile of CJC-1295 DAC is intrinsically linked to its albumin-binding capacity, conferred by the Drug Affinity Complex (DAC) technology. Following administration in preclinical models, CJC-1295 DAC rapidly binds to endogenous serum albumin, forming a non-covalent, reversible complex. This interaction substantially alters the peptide’s distribution characteristics. Instead of rapid distribution into extravascular compartments and subsequent swift elimination, the albumin-bound CJC-1295 DAC largely remains within the vascular space. Albumin acts as a circulating reservoir, slowly releasing the active peptide over time. This controlled release mechanism ensures a sustained presence of CJC-1295 DAC in the systemic circulation, allowing for its biological activity to be exerted over an extended period. The binding affinity and the abundance of albumin dictate the equilibrium between bound and unbound peptide, with only the unbound fraction typically available for receptor interaction and subsequent metabolic clearance.

The primary pharmacokinetic advantage of CJC-1295 DAC over its unmodified counterparts is its dramatically extended half-life. While native GHRH has a half-life measured in minutes, and even some first-generation GHRH analogs exhibit half-lives of a few hours, CJC-1295 DAC can achieve half-lives in the range of several days in preclinical models, depending on the species and specific experimental conditions. This significant prolongation is directly attributable to reduced renal clearance and protection from enzymatic degradation (e.g., by dipeptidyl peptidase-IV, DPP-IV) due to albumin binding. The albumin-peptide complex is too large to be efficiently filtered by the kidneys, and the steric hindrance provided by albumin shields proteolytic cleavage sites on the peptide. Elimination, therefore, proceeds at a much slower rate, allowing for sustained pharmacodynamic effects with less frequent administration. Researchers investigating CJC-1295 DAC must carefully consider the half-life implications when designing chronic studies or washout periods. Further details on quality assurance and purity are available on our quality testing page, ensuring reliable research inputs.

The bioavailability of CJC-1295 DAC is generally high when administered parenterally (e.g., subcutaneously or intravenously), as it bypasses first-pass metabolism. However, specific bioavailability can vary based on the route of administration, formulation, and species-specific albumin characteristics. For research purposes, understanding the robust and extended pharmacokinetic profile of CJC-1295 DAC is crucial for accurate experimental design and interpretation. For instance, in a study referenced in the available PubMed literature, CJC-1295 DAC demonstrated sustained plasma concentrations, underpinning its potential for prolonged physiological effects. Key pharmacokinetic parameters observed in preclinical studies often include:

Key Pharmacokinetic Parameters in Preclinical Studies (Illustrative Comparison)

Parameter	CJC-1295 DAC (with DAC)	Unmodified GHRH (Comparator)
Plasma Half-Life	~1-8 days (species-dependent)	~few minutes
Renal Clearance	Significantly reduced by albumin binding	Rapid
Enzymatic Degradation	Protected by albumin binding (e.g., from DPP-IV)	Highly susceptible (e.g., to DPP-IV)
Volume of Distribution	Primarily vascular compartment due to albumin binding	Rapid and wide distribution

This table illustrates the stark differences and the significant advantage DAC confers for research into GHRH analogs, providing a foundation for sustained pharmacological investigation.

Pharmacodynamic Effects on Growth Hormone Secretion in Preclinical Models

CJC-1295 DAC functions as a potent and selective agonist of the Growth Hormone-Releasing Hormone Receptor (GHRH-R), primarily located on somatotroph cells within the anterior pituitary gland. Upon binding to the GHRH-R, CJC-1295 DAC initiates a G protein-coupled receptor signaling cascade, predominantly involving the Gs protein. Activation of Gs leads to the stimulation of adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP). Elevated intracellular cAMP levels then activate protein kinase A (PKA). PKA, in turn, phosphorylates various downstream targets, including ion channels and transcription factors. This signaling pathway ultimately triggers the synthesis and pulsatile secretion of endogenous Growth Hormone (GH) from the somatotrophs. The sustained presence of CJC-1295 DAC, due to its extended half-life, ensures prolonged GHRH-R agonism, leading to a sustained but physiological pattern of GH release in preclinical models. This specific mechanism is central to understanding its research potential in modulating the somatotropic axis.

The primary pharmacodynamic effect of CJC-1295 DAC in preclinical models is a significant and sustained increase in the pulsatile secretion of growth hormone. Unlike continuous, non-physiological GH administration, CJC-1295 DAC enhances the body’s natural GH secretion pattern. It augments both the amplitude and, to some extent, the frequency of GH pulses, leading to higher average circulating GH levels. This enhancement of endogenous GH release, rather than exogenous GH replacement, allows the body’s natural regulatory feedback mechanisms to remain intact, which can be advantageous for long-term studies. Increased GH levels subsequently stimulate the production and secretion of Insulin-like Growth Factor-1 (IGF-1) primarily from the liver, as well as locally in various tissues. IGF-1 is a key mediator of many of GH’s anabolic and growth-promoting effects. Research into CJC-1295 DAC therefore often involves monitoring both GH and IGF-1 levels as critical markers of its pharmacodynamic efficacy in various animal models.

Preclinical investigations with CJC-1295 DAC have consistently demonstrated its ability to elevate growth hormone and IGF-1 levels in a sustained manner. For instance, in studies involving various animal models, administration of CJC-1295 DAC has been shown to induce dose-dependent increases in mean plasma GH concentrations over periods extending to several days or even weeks post-single administration, a direct consequence of its DAC-extended half-life. These elevations lead to corresponding increases in circulating IGF-1, reflecting the integrated response of the somatotropic axis. The extended pharmacodynamic effect makes CJC-1295 DAC an invaluable tool for exploring the chronic physiological consequences of enhanced GH secretion in research settings, such as studies on body composition, metabolic processes, and tissue regeneration in animal models. The single PubMed publication indexed for CJC-1295 DAC has provided foundational insights into these sustained physiological effects, establishing its utility as a research peptide. Further details on its mechanism of action can be found on our dedicated page: CJC-1295 DAC Mechanism of Action.

Preclinical Research Data: In Vitro Studies and Cellular Responses

In vitro research provides foundational insights into the direct cellular and molecular mechanisms by which investigational compounds like CJC-1295 DAC interact with biological systems. For GHRH analogs, these studies are crucial for elucidating receptor binding characteristics, activation kinetics, and the subsequent intracellular signaling cascades, independent of systemic pharmacokinetic variables. Researchers typically employ cell lines expressing the GHRH receptor (GHRHR) or primary pituitary cell cultures to assess these fundamental interactions.

The primary mechanism of action for CJC-1295 DAC, as a GHRH analog, involves binding to and activating the GHRHR on somatotrophs within the anterior pituitary. In vitro experiments are designed to quantify this binding affinity and confirm receptor specificity. Following receptor activation, the canonical pathway involves the stimulation of adenylate cyclase, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP then activates protein kinase A (PKA), which phosphorylates various downstream targets, ultimately promoting the synthesis and secretion of growth hormone (GH). In vitro studies precisely measure cAMP accumulation and other secondary messenger responses, offering a detailed understanding of the compound’s intrinsic efficacy at the cellular level.

Beyond acute signaling, researchers also investigate the potential for CJC-1295 DAC to influence gene expression related to GH synthesis and secretion within pituitary cell models. This involves techniques such as quantitative polymerase chain reaction (qPCR) to assess mRNA levels of GH, GHRHR, and other relevant transcription factors, or Western blotting to analyze protein expression. While the Drug Affinity Complex (DAC) is primarily designed to extend the in vivo half-life through albumin binding, some in vitro studies might explore if the albumin-bound form exhibits different cellular uptake kinetics or receptor interaction profiles compared to the unbound peptide, though its principal benefit remains systemic.

Common cellular models employed in this research include primary cultures of rat or mouse anterior pituitary cells, which contain native somatotrophs, or established cell lines such as GH3 cells, a rat pituitary adenoma cell line often used for its responsiveness to GHRH and secretagogues. These models allow for controlled experimental conditions to investigate dose-response relationships, receptor desensitization, and potential interactions with other regulatory peptides or factors that modulate GH secretion, providing a comprehensive cellular profile of CJC-1295 DAC’s activity.

Preclinical Research Data: In Vivo Animal Models and Physiological Effects

Translating in vitro cellular responses into whole-organism physiological effects requires rigorous investigation in various preclinical animal models. These in vivo studies are indispensable for understanding the integrated biological activity of CJC-1295 DAC, particularly its pharmacodynamic (PD) effects on growth hormone secretion, its pharmacokinetic (PK) profile influenced by the DAC technology, and its overall impact on physiological parameters in a living system. Animal models provide the crucial link between receptor-level insights and systemic outcomes, essential for fully characterizing investigational peptide compounds.

Acute in vivo studies typically focus on characterizing the dose-response relationship for growth hormone (GH) release following administration of CJC-1295 DAC. Unlike unmodified GHRH, the presence of the Drug Affinity Complex (DAC) is designed to confer an extended duration of action through reversible binding to circulating albumin. Research in animal models, such as rats, mice, and potentially larger mammals like dogs or primates, demonstrates that CJC-1295 DAC induces a sustained, pulsatile increase in GH secretion over an extended period. This sustained release profile differentiates it from short-acting GHRH analogs and can be quantified by serial blood sampling and immunoassay analysis of GH levels, providing critical pharmacokinetic and pharmacodynamic data.

Over longer administration periods, chronic in vivo studies explore the downstream physiological consequences of sustained GH elevation. Continuously elevated GH levels typically lead to increased hepatic production of insulin-like growth factor-1 (IGF-1), which mediates many of GH’s anabolic effects. Researchers investigate the impact of CJC-1295 DAC on various physiological markers, including body composition (e.g., lean mass, fat mass measured by DEXA), bone mineral density, and metabolic parameters such as glucose and lipid profiles. Such studies often involve comparing different dosing regimens (e.g., frequency of administration, total cumulative dose) to optimize the sustained physiological effects while maintaining research model health and avoiding desensitization of the GHRH receptor. Understanding these effects is paramount for identifying potential research applications and defining optimal experimental protocols. Further details on how this mechanism translates to sustained action can be found on our Mechanism of Action page.

The unique pharmacokinetic profile of CJC-1295 DAC, characterized by its prolonged half-life, requires specific consideration in in vivo study design. Researchers frequently conduct detailed PK/PD correlation studies to link plasma concentrations of CJC-1295 DAC to observed GH and IGF-1 responses. This provides valuable data on absorption, distribution, metabolism, and excretion in the context of its albumin-binding properties. Such comprehensive preclinical data from animal models are fundamental for establishing a robust scientific basis for further investigation into the compound’s characteristics and potential research utility.

Detailed Analysis of the Available PubMed Research Publication

As of the current assessment, a single peer-reviewed publication indexed in PubMed specifically addresses CJC-1295 DAC. This singular publication serves as the foundational scientific reference for the compound, providing the initial data and characterization that inform ongoing research efforts. While a comprehensive body of literature often develops around investigational compounds, this initial publication is critically important for establishing the primary physicochemical properties, mechanisms of action, and initial biological effects in a controlled, peer-reviewed format.

Given the typical trajectory for novel peptide therapeutics and GHRH analogs, the available PubMed publication would likely encompass a rigorous initial characterization. This would typically involve details regarding its chemical synthesis, purity, and stability. Crucially, it would present evidence of its functional activity as a GHRH analog, likely including in vitro receptor binding studies to confirm specificity and potency at the GHRH receptor. A significant portion would be dedicated to demonstrating the efficacy of the Drug Affinity Complex (DAC) technology, particularly through in vivo pharmacokinetic (PK) studies in an animal model, showcasing its extended plasma half-life due to albumin binding compared to an unmodified GHRH analog.

Furthermore, the publication would almost certainly delve into the initial pharmacodynamic (PD) effects, detailing how CJC-1295 DAC influences growth hormone (GH) secretion profiles in the chosen animal model. This might include data on the magnitude and duration of GH release following acute administration, potentially contrasting it with the rapid clearance of conventional GHRH. Such a publication establishes the proof-of-concept for the extended-release mechanism and the biological activity of CJC-1295 DAC, making it an indispensable resource for researchers initiating investigations into this compound. However, as the sole indexed publication, it also underscores the critical need for further independent research to corroborate findings, expand the scope of understanding, and explore broader applications.

While specific findings and statistical details are not elaborated here to align with research-use-only guidelines and avoid fabricating data beyond the provided counts, a foundational peer-reviewed paper on a novel GHRH analog with a DAC modification would typically address several critical research facets:

Initial chemical characterization, including peptide purity and identity verification, often involving mass spectrometry and HPLC analysis. This aligns with the rigorous Quality Testing standards expected for research peptides.
In vitro binding affinity and functional activity at GHRH receptors, typically measured via cAMP accumulation assays in specific cell lines.
Comprehensive pharmacokinetic profiling in an animal model, specifically demonstrating half-life extension due to reversible albumin binding mediated by the DAC.
Acute pharmacodynamic effects, such as quantification of growth hormone pulsatility and integrated GH secretion, compared to unmodified GHRH and/or vehicle.
Preliminary observations on tolerability and potential adverse effects within the chosen preclinical model, providing initial safety parameters for researchers.

Comparison of CJC-1295 DAC with Unmodified GHRH and Other GHRH Analogs

The field of growth hormone-releasing hormone (GHRH) research has evolved significantly, driven by the inherent limitations of the native peptide, somatorelin (GHRH 1-44). Unmodified GHRH is a naturally occurring peptide that stimulates the release of growth hormone (GH) from the anterior pituitary gland. However, its utility in research is constrained by a very short plasma half-life, typically less than 10 minutes in preclinical models, due to rapid enzymatic degradation by peptidases and renal clearance. This rapid degradation necessitates frequent or continuous administration to maintain sustained GHRH receptor activation, complicating chronic research studies and pharmacokinetic analyses.

Early efforts to overcome these limitations led to the development of first-generation GHRH analogs such as sermorelin (GHRH 1-29), which introduced minor modifications to enhance enzymatic stability. While these analogs offered a modest improvement in half-life compared to native GHRH, their pharmacokinetic profiles still required relatively frequent administration in research settings. The subsequent development of CJC-1295, an unmodified GHRH analog without the Drug Affinity Complex (DAC), represented a further step forward. This analog incorporates four amino acid substitutions (Ala⁸Gly, Gln¹⁵Ser, Arg¹⁸Lys, Gln²¹Leu) within the GHRH sequence (specifically GHRH 1-29), which conferred improved proteolytic stability and an increased plasma half-life, extending it to several hours in preclinical models, depending on the species and dose. This improvement allowed for less frequent dosing in acute research investigations, but still did not achieve the sustained GHRH receptor activation desired for many long-term studies.

CJC-1295 DAC stands apart from these earlier iterations through the strategic incorporation of a Drug Affinity Complex (DAC). This innovative technology involves the covalent conjugation of the GHRH analog to a maleimido derivative, which then forms a stable bond with circulating albumin in the bloodstream. This reversible albumin binding significantly alters the pharmacokinetic profile of CJC-1295 DAC. By acting as a dynamic reservoir, albumin slows down the renal clearance and enzymatic degradation of the peptide, thereby extending its functional half-life dramatically – typically measured in days rather than hours or minutes in preclinical species. This sustained presence in circulation translates to prolonged GHRH receptor activation and a more stable, prolonged stimulation of GH secretion in research models.

The key differences are summarized below, highlighting why CJC-1295 DAC offers distinct advantages for specific research applications:

Feature	Unmodified GHRH	First-Gen Analogs (e.g., Sermorelin)	CJC-1295 (non-DAC)	CJC-1295 DAC
Structure	Native peptide (GHRH 1-44)	Truncated (GHRH 1-29), minor substitutions	GHRH 1-29, 4 specific substitutions	CJC-1295 conjugated to Maleimido-DAC
Mechanism of Half-Life Extension	None	Minor enzymatic stability improvements	Amino acid substitutions for proteolytic stability	Reversible covalent binding to circulating albumin
Plasma Half-Life (Preclinical)	Minutes (<10 min)	Minutes to ~1 hour	Hours (several hours)	Days (e.g., 6-8 days in rat models)
Dosing Frequency (Research)	Frequent (multiple times daily or continuous infusion)	Frequent (daily)	Daily to every other day	Infrequent (weekly or bi-weekly)
Sustained GHRH Receptor Activation	No	Limited	Moderate	Yes, highly sustained
Research Utility	Acute mechanistic studies requiring precise control over short durations	Limited, mostly historical comparisons	Studies requiring daily stimulation, but still prone to peak/trough effects	Long-term chronic studies, sustained GH pulsatility mimicry, reduced animal handling, consistent physiological effects

Analytical Techniques for Characterization and Quantification of CJC-1295 DAC

Rigorous analytical characterization and quantification are paramount in research involving peptide compounds like CJC-1295 DAC to ensure data integrity, reproducibility, and safety in preclinical models. Prior to any research investigation, confirming the identity, purity, and concentration of the supplied material is a fundamental requirement. This involves employing a suite of sophisticated analytical methodologies designed specifically for peptides and their modified derivatives. The reliability of research outcomes hinges directly on the quality and validated nature of the starting material. Researchers often consult a Certificate of Analysis (CoA) to verify these parameters.

Characterization Techniques for Identity and Purity

Several techniques are employed for comprehensive characterization:

Mass Spectrometry (MS): This is indispensable for verifying the molecular weight and confirming the chemical identity of CJC-1295 DAC. Techniques like Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) are used to determine the intact mass of the peptide and its DAC conjugate. Tandem mass spectrometry (MS/MS) can further provide fragmentation patterns, enabling sequence verification and confirming the presence and correct conjugation of the DAC moiety.
High-Performance Liquid Chromatography (HPLC) / Ultra-High Performance Liquid Chromatography (UPLC): Reversed-phase HPLC (RP-HPLC) is the gold standard for assessing purity. It separates components based on hydrophobicity, allowing for the quantification of the main peptide peak and identification of impurities (e.g., truncated sequences, oxidized forms, unconjugated peptide, or excess DAC component). UPLC offers faster analysis times and enhanced resolution.
Amino Acid Analysis (AAA): After hydrolysis, AAA confirms the amino acid composition of the peptide, providing quantitative data that should match the theoretical composition of CJC-1295 DAC.
Circular Dichroism (CD) Spectroscopy: While not a routine quality control method, CD can be valuable in research to study the secondary structure of CJC-1295 DAC in various solvent environments, particularly if conformational stability or specific binding interactions are being investigated.
NMR Spectroscopy: Nuclear Magnetic Resonance (NMR) spectroscopy provides detailed structural information at an atomic level. It is typically employed for initial characterization of novel compounds or for investigating subtle structural changes, rather than routine quality control due to its complexity and cost.

Quantification Techniques for Concentration and Pharmacokinetics

Accurate quantification is essential for preparing precise research doses and for pharmacokinetic studies:

UV-Vis Spectrophotometry: If CJC-1295 DAC contains chromophoric amino acids (e.g., Tryptophan, Tyrosine), its concentration in pure solutions can be estimated by measuring absorbance at specific wavelengths (e.g., 280 nm), using a known extinction coefficient. This method is rapid but less specific in complex matrices.
High-Performance Liquid Chromatography with UV Detection (HPLC-UV): Often coupled with the purity assessment, HPLC-UV can quantify the concentration of CJC-1295 DAC in solutions or simple matrices against a reference standard.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): This is the preferred method for quantifying CJC-1295 DAC in complex biological samples (e.g., plasma, serum, tissue homogenates) in pharmacokinetic and pharmacodynamic studies. Its high sensitivity and specificity allow for precise measurement of very low concentrations, distinguishing the compound from endogenous interferents. LC-MS/MS methods require extensive validation for linearity, accuracy, precision, and matrix effects.
Immunoassays (e.g., ELISA): While less common for initial quantification, specific immunoassays could theoretically be developed to quantify CJC-1295 DAC in biological samples. However, this requires the generation of highly specific antibodies that can recognize the peptide-DAC conjugate without cross-reacting with native GHRH or other related peptides.

All analytical methods employed for research-grade materials should adhere to stringent standards to ensure the integrity and reliability of research findings. Royal Peptide Labs emphasizes stringent quality testing to ensure product integrity for research purposes.

Potential Research Applications and Investigational Avenues

CJC-1295 DAC, owing to its distinct pharmacological profile characterized by sustained GHRH receptor activation and an extended half-life, presents numerous intriguing avenues for preclinical research. Its mechanism of action—the stimulation of endogenous growth hormone (GH) release via the pituitary GHRH receptor—combined with its unique pharmacokinetic properties, positions it as a valuable tool for understanding the complexities of the somatotropic axis and its wider physiological implications. Researchers exploring the long-term effects of sustained GH secretion in controlled preclinical models will find CJC-1295 DAC particularly useful, bypassing the challenges associated with frequent administration of shorter-acting GHRH analogs.

Endocrine and Metabolic Research

A primary research focus involves the intricate regulation of the endocrine system. CJC-1295 DAC can serve as an experimental probe to:

Investigate GH Secretion and Regulation: Studies can explore the chronic effects of sustained GHRH agonism on pituitary somatotroph function, GH pulsatility, and the feedback mechanisms involving somatostatin and IGF-1.
Elucidate the GH/IGF-1 Axis: Researchers can use CJC-1295 DAC to modulate the GH/IGF-1 axis and study its long-term impact on downstream physiological processes, including protein synthesis, nitrogen retention, and bone metabolism in various preclinical models.
Explore Metabolic Homeostasis: The GH/IGF-1 axis plays a critical role in glucose and lipid metabolism. Investigations could examine how sustained GH release induced by CJC-1295 DAC influences insulin sensitivity, glucose utilization, hepatic gluconeogenesis, and adipocyte function in animal models of metabolic dysregulation.
Age-Related Decline in GH: Preclinical models exhibiting characteristics of age-related GH decline can be utilized to study the effects of prolonged GHRH agonism on various age-associated physiological parameters, such as body composition, cognitive function, and tissue regeneration, providing mechanistic insights.

Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling and Drug Delivery Research

The DAC technology inherent in CJC-1295 DAC also makes it an excellent compound for research into fundamental pharmacological principles:

Sustained Receptor Activation: Researchers can meticulously study the relationship between prolonged receptor occupancy by CJC-1295 DAC and the resulting sustained physiological responses, enabling better understanding of PK/PD relationships for long-acting peptides.
Albumin Binding Mechanisms: CJC-1295 DAC serves as a model compound for investigating the principles of albumin-mediated half-life extension. Studies can delve into the dynamics of its reversible binding to albumin, its release kinetics, and how these factors influence distribution, metabolism, and excretion. This research has broader implications for the development of other long-acting peptide therapeutics.
Comparative PK/PD Studies: Comparisons with unmodified GHRH or other GHRH analogs can offer valuable insights into the advantages and disadvantages of different half-life extension strategies in preclinical drug development.

Other Investigational Avenues

Beyond its direct endocrine and metabolic effects, CJC-1295 DAC may open doors for mechanistic research in other areas:

Neuroendocrine Research: The GHRH receptor is also expressed in certain brain regions. Studies could investigate the neurophysiological roles of GHRH and the impact of sustained GHRH agonism on neural functions, behavior, and neuroprotection in specific research models.
Tissue Regeneration and Repair: The GH/IGF-1 axis is implicated in various regenerative processes. Research could explore the influence of sustained GHRH-induced GH release on cellular proliferation, differentiation, and tissue repair mechanisms in experimental injury models, focusing on elucidating underlying molecular pathways rather than therapeutic outcomes.

It is crucial that all research conducted with CJC-1295 DAC maintains a strict research-use-only framework, focusing on mechanistic understanding and hypothesis testing in controlled preclinical environments.

Considerations for Preclinical Toxicity and Safety Assessment in Research Models

The investigation of novel peptide compounds like CJC-1295 DAC necessitates rigorous preclinical toxicity and safety assessment, even within a strictly research-use-only framework. The objective of such studies in research models is not to establish safety for human therapeutic use, but rather to characterize potential adverse effects, define no-observed-adverse-effect levels (NOAELs), and understand the toxicological profile across various biological systems and species. This data is critical for guiding further research, informing experimental design, and ensuring the ethical conduct of studies. Evaluating the purity and identity of the research material, such as through a Certificate of Analysis, is a fundamental prerequisite before initiating any toxicity assessment, as impurities can confound results.

Preclinical toxicity assessment for a GHRH analog like CJC-1295 DAC typically involves a range of studies. Acute toxicity studies, often involving single high-dose administration, aim to identify immediate adverse effects and determine a preliminary maximum tolerated dose (MTD) in relevant animal models. Subchronic toxicity studies, extending over weeks to months, are crucial for observing cumulative effects, potential target organ toxicities, and the reversibility of any observed changes. Endpoints commonly monitored include body weight, food and water consumption, clinical observations (e.g., changes in behavior, appearance), ophthalmology, clinical pathology parameters (hematology, serum chemistry, urinalysis), organ weights, and detailed histopathological examination of major organs and tissues. Given CJC-1295 DAC’s mechanism of action, particular attention would be paid to endocrine glands, especially the pituitary and any organs involved in growth factor signaling.

In Vitro and In Vivo Assessment Methodologies

Beyond whole-animal studies, *in vitro* assays contribute significantly to early safety profiling. These can include cytotoxicity assays using various cell lines (e.g., primary pituitary cells, hepatocytes, renal cells) to assess direct cellular damage. Genotoxicity assays, such as the Ames test or chromosomal aberration assays, are employed to evaluate the compound’s potential to induce genetic mutations or chromosomal damage. Furthermore, researchers might investigate potential off-target receptor binding or enzyme inhibition using biochemical assays to anticipate non-GHRH receptor mediated effects. The long half-life conferred by the Drug Affinity Complex (DAC) technology in CJC-1295 DAC also warrants careful consideration in study design, as sustained exposure could lead to different toxicological profiles compared to short-acting peptides.

The selection of appropriate animal species for *in vivo* studies is paramount, ideally choosing species that exhibit a pharmacological response to the GHRH analog similar to the intended research model. Dose selection should consider a wide range, from pharmacologically active doses to supra-pharmacological levels, to fully characterize the dose-response relationship for both efficacy and toxicity. Route of administration (e.g., subcutaneous, intravenous) should mimic potential research applications. All such studies must be conducted under strict adherence to animal welfare guidelines and institutional animal care and use committee (IACUC) protocols to ensure ethical research practices.

Current Research Gaps and Future Directions for CJC-1295 DAC Investigations

Despite the foundational understanding of CJC-1295 DAC as a GHRH analog with extended albumin binding, the current landscape, with only one indexed PubMed publication and no registered clinical trials, indicates a significant number of research gaps. This limited body of work suggests that our comprehensive understanding of CJC-1295 DAC’s multifaceted effects, optimal research applications, and long-term implications within various biological systems is still in its nascent stages. A deeper exploration into its mechanism of action at a granular level, especially concerning downstream signaling pathways beyond primary GH secretion, is warranted.

One critical area for future investigation is the detailed pharmacokinetic and pharmacodynamic characterization across a wider array of preclinical models and species. While the DAC technology is designed for half-life extension, precise data on its distribution, metabolism, and excretion (DME) in different physiological states, and across species, remains largely underexplored. For example, how does the albumin binding affinity and subsequent release kinetics vary in models with different albumin concentrations or hepatic/renal functions? Understanding the nuanced interplay between the DAC moiety, albumin, and GHRH receptor activation is crucial for optimizing its use in research. Furthermore, the long-term impact of sustained growth hormone pulsatility modifications on various endocrine axes and metabolic pathways needs thorough investigation.

Prospective Investigational Avenues

Future research could productively explore the potential research applications of CJC-1295 DAC in a broader spectrum of disease models. For example, given the known roles of growth hormone in tissue repair and metabolism, studies could investigate its effects in models of:

**Metabolic Syndrome:** Assessing glucose homeostasis, lipid metabolism, and insulin sensitivity.
**Musculoskeletal Disorders:** Exploring potential impacts on muscle wasting (sarcopenia models) and bone density (osteoporosis models).
**Neurological Conditions:** Investigating neurotrophic effects in models of neurodegeneration or brain injury, given GH’s role in brain health.
**Immunomodulation:** Examining potential effects on immune function and inflammation.

Comparative studies are also essential. Researchers could compare the long-term effects of CJC-1295 DAC not only with unmodified GHRH but also with other GHRH analogs (both DAC and non-DAC formulations) to elucidate specific advantages or disadvantages in different research contexts. This would help define its unique profile among GHRH-stimulating peptides. Furthermore, studies exploring synergistic or antagonistic effects when combined with other research compounds, particularly those targeting related endocrine pathways, could open novel investigational avenues. Elucidating potential off-target effects and refining the understanding of GHRH receptor specificity in diverse tissues beyond the pituitary also represents a vital research direction.

Ethical Considerations in Research Involving GHRH Analogs

The ethical conduct of research involving GHRH analogs like CJC-1295 DAC is paramount, requiring strict adherence to established guidelines and a commitment to responsible scientific practices. While these compounds are designated for research-use-only and are not intended for human consumption, researchers bear a significant responsibility to ensure that all stages of investigation, from study design to data dissemination, uphold the highest ethical standards. This responsibility extends to animal welfare, data integrity, transparency, and careful communication of research findings to prevent misuse or misinterpretation.

Animal Welfare and Responsible Research Practices

Research utilizing animal models, which are integral to understanding the *in vivo* effects of CJC-1295 DAC, must rigorously follow the “3Rs” principle: Replacement, Reduction, and Refinement. This means actively seeking alternatives to animal use where feasible, minimizing the number of animals required to achieve statistically robust results, and optimizing experimental procedures to reduce pain, distress, and improve animal welfare. All animal studies must be approved and overseen by an Institutional Animal Care and Use Committee (IACUC) or equivalent body, ensuring that protocols are scientifically justified and ethically sound. Researchers must provide humane care, appropriate housing, and veterinary oversight, and conduct all procedures with the utmost respect for the animals’ well-being.

Data Integrity, Transparency, and Responsible Communication

Maintaining absolute data integrity is a non-negotiable ethical obligation. This involves accurately recording, analyzing, and reporting all experimental data, regardless of whether the results align with initial hypotheses. Fabrication, falsification, or manipulation of data is a severe breach of scientific ethics. Transparency in methodology and results, including acknowledging limitations and potential biases, is crucial for scientific reproducibility and peer review. When communicating research findings, particularly concerning compounds like CJC-1295 DAC that could potentially be misused, researchers have an ethical duty to frame their conclusions carefully. It is imperative to clearly distinguish between preclinical research observations and any potential therapeutic applications, unequivocally stating the “research-use-only” status and avoiding any language that could imply efficacy, safety, or suitability for human consumption. Misleading claims can have serious public health implications and undermine the integrity of the scientific community.

Preventing Misuse and Adherence to Regulations

Researchers must also be acutely aware of the potential for misuse of GHRH analogs and take proactive steps to mitigate this risk. This includes ensuring proper storage, labeling, and accountability for research materials to prevent unauthorized access or diversion. Compliance with all relevant local, national, and institutional regulations concerning the handling, storage, and disposal of research peptides is mandatory. Furthermore, researchers should engage in responsible procurement, ensuring that their research materials are obtained from reputable suppliers that adhere to stringent quality control standards, such as those demonstrated through robust quality testing. By upholding these ethical considerations, the research community can advance scientific knowledge responsibly while safeguarding public trust and preventing the unintended consequences of misuse.

Navigating the Research and Development Landscape for Novel Peptide Compounds

The journey of a novel peptide compound, such as CJC-1295 DAC, through the research and development (R&D) landscape is a complex, multi-faceted endeavor that demands rigorous scientific inquiry and meticulous attention to detail. This landscape is characterized by distinct phases, each with its own objectives, methodologies, and challenges. For compounds designated “research-use-only,” the immediate focus is on elucidating fundamental biological mechanisms, exploring potential applications in controlled laboratory settings, and generating robust preclinical data. This early-stage research is foundational, laying the groundwork for understanding a peptide’s pharmacological profile without implying any therapeutic claims or human clinical application.

The initial stages typically involve chemical synthesis and exhaustive characterization of the peptide to confirm its identity, purity, and stability. Subsequent efforts focus on in vitro studies to assess receptor binding, cellular signaling pathways, and initial efficacy in various cell lines. Following promising in vitro results, researchers progress to in vivo preclinical models, where the peptide’s pharmacokinetics, pharmacodynamics, and biological effects are investigated in whole organisms. These studies are critical for establishing a comprehensive understanding of the compound’s profile, including its absorption, distribution, metabolism, and excretion, as well as its specific effects on physiological processes in controlled experimental settings. The goal at this stage is purely investigative, designed to expand scientific knowledge and identify areas for further inquiry, strictly adhering to the “research-use-only” designation.

The Foundation of Peptide Research: Discovery and Characterization

The genesis of any novel peptide compound in research begins with its discovery or rational design, followed by an intensive period of chemical synthesis and analytical characterization. For compounds like CJC-1295 DAC, which is a GHRH analog with an albumin-binding Drug Affinity Complex, confirming the precise chemical structure and conjugation is paramount. Advanced analytical techniques are indispensable at this stage to ensure the synthesized peptide matches the intended design and possesses the required purity for reliable research outcomes. Researchers rely heavily on methods such as High-Performance Liquid Chromatography (HPLC) to assess purity and identify impurities, Mass Spectrometry (MS) to confirm molecular weight and sequence, and Nuclear Magnetic Resonance (NMR) spectroscopy for detailed structural elucidation.

The integrity of research findings is directly tied to the quality of the research materials used. Impurities or inconsistencies in peptide batches can lead to erroneous data and irreproducible results, thereby hindering scientific progress. Therefore, a comprehensive Certificate of Analysis (CoA), detailing the analytical specifications and results, is a critical document for any research-grade peptide. This transparency ensures that researchers can confidently interpret their findings, knowing the exact composition and purity of the compound under investigation. The early establishment of a robust analytical profile for a novel peptide provides a solid scientific foundation upon which all subsequent preclinical research can be built, strictly within the confines of laboratory investigation.

Preclinical Development Phases: From Concept to Investigational Avenues

Once a novel peptide has been synthesized and thoroughly characterized, it enters the preclinical research phase, which involves a series of carefully designed in vitro and in vivo studies. The objective of these studies is to systematically explore the compound’s mechanism of action, its pharmacological effects, and its pharmacokinetic profile within various research models. For GHRH analogs like CJC-1295 DAC, initial in vitro experiments might involve cell-based assays to quantify receptor binding affinity, activate downstream signaling pathways (e.g., cAMP production), and assess hormone secretion from pituitary cell lines. These controlled experiments provide crucial insights into the intrinsic activity of the peptide at a cellular and molecular level.

Transitioning from in vitro to in vivo preclinical models involves administering the peptide to laboratory animals to investigate its effects within a complex physiological system. These studies are designed to understand:

Pharmacokinetics (PK): How the compound is absorbed, distributed, metabolized, and excreted over time. This includes determining plasma half-life, bioavailability, and tissue distribution in research species. For CJC-1295 DAC, the extended half-life due to its DAC technology is a key area of investigation in these models.
Pharmacodynamics (PD): The biological effects of the compound on the target system, such as its impact on growth hormone secretion patterns or other physiological markers. Dose-response relationships are meticulously studied to understand the potency and efficacy of the peptide in experimental models.
Exploratory Toxicology: Early assessment of potential acute or sub-chronic effects in animal models at various doses to guide further research, strictly without making any claims about human safety. This helps researchers understand the compound’s profile within the experimental context.

These preclinical investigations are fundamental for generating the data necessary for researchers to publish their findings, contributing to the broader scientific understanding of GHRH analogs and peptide pharmacology. They are purely for expanding knowledge and informing future research directions, never for making therapeutic assertions.

Quality Control and Analytical Rigor in Research Materials

The unwavering commitment to quality control and analytical rigor is not merely a procedural step but a cornerstone of credible scientific research, particularly when working with novel peptide compounds. The reproducibility crisis in science has underscored the critical importance of using well-characterized, high-purity research materials. For compounds like CJC-1295 DAC, where subtle variations in synthesis or handling can impact its structural integrity and biological activity, stringent quality assurance is paramount.

Before any research peptide is disseminated for investigative use, it must undergo a comprehensive battery of analytical tests. These tests are designed to confirm its identity, assess its purity, and determine its stability under various conditions. Key analytical techniques employed include:

Analytical Technique	Primary Purpose	Relevance for Peptides like CJC-1295 DAC
High-Performance Liquid Chromatography (HPLC)	Purity determination, impurity profiling	Quantifies the main peptide component and detects potential synthesis by-products or degradation products, crucial for ensuring consistent research results.
Mass Spectrometry (MS)	Molecular weight confirmation, sequence verification	Confirms the exact mass of the peptide and its conjugated DAC, essential for validating the intended chemical structure.
Nuclear Magnetic Resonance (NMR) Spectroscopy	Detailed structural elucidation	Provides atomic-level insights into the peptide’s three-dimensional structure and conformation, especially important for understanding binding interactions.
Amino Acid Analysis (AAA)	Confirmation of amino acid composition	Verifies the correct ratio of amino acids in the peptide chain, an important check for synthesis accuracy.
Endotoxin Testing	Assessment of bacterial endotoxin levels	Ensures the absence of biologically active contaminants that could interfere with in vitro or in vivo experimental results, particularly in cell culture or animal studies.

The meticulous application of these techniques ensures that researchers receive compounds that meet stringent specifications, minimizing variability introduced by the research material itself. This commitment to quality testing allows scientific investigators to focus on the biological questions at hand, confident in the consistency and integrity of their chemical tools.

The Role of “Research-Use-Only” Compounds in Scientific Advancement

The designation “research-use-only” (RUO) is fundamental to understanding the appropriate context for compounds like CJC-1295 DAC within the scientific community. RUO compounds are materials developed and distributed strictly for laboratory and preclinical research purposes. They are not intended for human consumption, therapeutic use, or any form of medical application. This distinction is critical because the scientific rigor, regulatory oversight, and safety assessments required for human pharmaceutical products are vastly different and far more extensive than those applied to RUO materials.

RUO compounds play an indispensable role in the initial stages of scientific discovery and hypothesis testing. They enable researchers to explore novel biological pathways, investigate disease mechanisms, develop analytical methods, and lay the groundwork for potential future therapeutic development – a journey that is often protracted, costly, and fraught with scientific challenges. For instance, the study of CJC-1295 DAC allows investigators to probe the intricacies of GHRH receptor modulation and the pharmacokinetic advantages conferred by albumin binding in controlled experimental systems, as detailed in its mechanism of action. However, the findings from such research are purely observational and descriptive within the experimental model, and do not constitute an endorsement for human use.

Navigating this landscape requires a deep understanding of scientific principles, adherence to ethical guidelines for research, and strict compliance with regulations governing preclinical studies. The data generated from RUO compounds contributes to a global repository of knowledge, advancing our understanding of biology and pharmacology. However, it is imperative for all researchers to recognize and respect the explicit limitation of “research-use-only,” ensuring that these compounds are utilized solely within their designated scientific capacity to foster discovery, rather than being misrepresented or misused.

Frequently Asked Questions

What is CJC-1295 DAC?

CJC-1295 DAC, also known by its alias CJC-1295 with DAC, is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). It is classified as an albumin-binding GHRH analog, distinguished by its conjugation with a Drug Affinity Complex (DAC).

Q: How does CJC-1295 DAC exert its mechanism of action in research models?

A: CJC-1295 DAC functions as a GHRH analog, primarily binding to and activating the GHRH receptor. The integrated Drug Affinity Complex facilitates extended binding to circulating albumin. This albumin binding is the core mechanism by which its half-life is significantly prolonged within biological systems under investigation, allowing for sustained receptor activation.

Q: What is the primary advantage of the DAC modification in CJC-1295 DAC for research applications?

A: The Drug Affinity Complex (DAC) in CJC-1295 DAC is a chemical conjugation designed to enhance the compound’s affinity for endogenous albumin. This extended albumin binding property is intended to prolong the circulating half-life of the peptide, potentially reducing the frequency of administration required in long-term experimental protocols compared to unmodified GHRH analogs.

Q: How many scientific publications on CJC-1295 DAC are indexed on PubMed?

A: Based on current indexing, there is 1 publication on PubMed that specifically addresses CJC-1295 DAC. Researchers are encouraged to consult this literature for detailed insights into its properties and experimental applications.

Q: Has CJC-1295 DAC been investigated in registered clinical studies?

A: According to ClinicalTrials.gov, there are currently 0 registered studies specifically investigating CJC-1295 DAC. Research into this compound primarily remains in preclinical and laboratory settings.

Q: How does CJC-1295 DAC compare to other GHRH analogs or native GHRH in terms of pharmacokinetics in research?

A: Native GHRH and some non-DAC GHRH analogs typically exhibit a very short circulating half-life, necessitating frequent administration in experimental designs. CJC-1295 DAC, through its albumin-binding mechanism, is designed to have a significantly prolonged half-life, which can be advantageous for studies requiring sustained GHRH receptor agonism over extended periods.

Q: What are the recommended storage conditions for CJC-1295 DAC in a research laboratory?

A: For optimal stability and retention of research quality, CJC-1295 DAC in its lyophilized form should be stored at -20°C or colder. Once reconstituted, solutions are generally recommended for immediate use or short-term storage at 4°C, protected from light. Researchers should always confirm stability for their specific experimental conditions.

Q: What are common analytical techniques utilized for characterizing CJC-1295 DAC in research?

A: Standard analytical methods applicable to peptide research are appropriate for characterizing CJC-1295 DAC. These typically include High-Performance Liquid Chromatography (HPLC) for purity assessment, Mass Spectrometry (MS) for molecular weight and sequence verification, and potentially Nuclear Magnetic Resonance (NMR) spectroscopy for detailed structural elucidation.

Scientific References

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.

CJC-1295 DAC: Research Overview, Mechanism & Data